Close Menu
NEW YORK (GenomeWeb News) – Diagnostics products and services firm Lab21 today said that it has raised £2.2 million ($3.2 million) from a round of financing with private equity investors.
 
The Cambridge, UK-based firm, which has diagnostics products and services focused on infectious diseases, oncology, and pharmacogenetics, said it would use the funds to further its acquisition plan and to establish its US operations in South Carolina with an eye toward expanding its North American presence.
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.